Table 4. Completed EGFR inhibitor trials in BTC/GEMOX.
| Treatment | Phase | No. of subjects | ORR | mPFS (m) | mOS (m) | Reference |
|---|---|---|---|---|---|---|
| GEMOX
GEMOX+erlotinib |
III |
268 |
16% 30% |
4.2
5.8 |
9.5
9.5 |
Lee et al, 2012 |
| GEMOX
GEMOX+
cetuximab |
II |
150 |
29% 23% |
5.5
6.1 |
12.4
11 |
Malka et al, 2012 |
| GEMOX
GEMOX+
cetuximab |
II |
122 |
17% 27% |
4.1
6.7 |
9.8
10.6 |
Chen et al, 2013 |
| GEMOX
Panitumumab |
II |
31 |
45% |
10.6 |
20.3 |
Hezel et al, 2010 |
| GEMOX
Cetuximab |
II |
30 |
63% |
8.8 |
15.2 |
Gruenberger et al, 2010 |
| Gemcitabine
Capecitabine
Cetuximab |
II |
34 |
18% |
7.8 |
14.5 |
Rubovszky et al, 2013 |
| GEMOX
Capecitabine
Panitumumab |
II |
46 |
33% |
8.3 |
10 |
Jensen et al, 2012 |
| Gemcitabine
Irinotecan
Panitumumab |
II |
31 |
31% |
9.7 |
12.7 |
Sohal et al, 2013 |
| Erlotinib (2nd line) | II | 42 | 8% | 2.6 | 7.5 | Philip et al, 2006 |
Abbreviations: BTC=biliary tract cancer; EGFR=epidermal growth factor receptor; GEMOX=in combination with gemcitabine and oxaliplatin; mOS=median overall survival; mPFS=median progression free survival; ORR=objective response rate.